SAN DIEGO, Oct. 29 /PRNewswire-FirstCall/ -- Genoptix, Inc. announced today the pricing of its initial public offering of 5,000,000 shares of common stock at a price of $17.00 per share. 4,285,714 shares are being offered by Genoptix and 714,286 shares are being offered by certain selling stockholders. In addition, Genoptix and the selling stockholders have granted to the underwriters a 30-day option to purchase up to an additional 750,000 shares of common stock. Genoptix common stock is expected to begin trading on the NASDAQ Global Market under the trading symbol "GXDX" on Tuesday, October 30, 2007.
The offering is being made through an underwriting syndicate led by Lehman Brothers Inc. acting as sole book-running manager. Banc of America Securities LLC is acting as joint lead manager and Cowen and Company, LLC as co-manager.
A registration statement relating to these securities was declared effective by the Securities and Exchange Commission on October 29, 2007. This offering is being made solely by means of written prospectus. Copies of the final prospectus relating to the offering may be obtained by contacting Lehman Brothers Inc., c/o Broadridge Integrated Distribution Services, 1155 Long Island Avenue, Edgewood, NY 11717, (fax): 631-254-7140, or e-mail email@example.com, or at the Securities and Exchange Commission's website at http://www.sec.gov.
This press release shall not constitute an offer to sell or a solicitation of an offer to buy, nor shall there be any sale of these securities in any state or jurisdiction in which such an offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.
About Genoptix, Inc.
Genoptix is a specialized laboratory service provider focused on delivering personalized and comprehensive diagnostic services to community- based hematologists and oncologists. Genoptix is headquartered in Carlsbad, California.
This press release contains forward-looking statements that are subject to risks and uncertainties that could cause actual results to differ materially from those set forth in the forward-looking statements. Actual results may differ materially from those projected. Genoptix disclaims, however, any intent or obligations to update these forward-looking statements.
Source: Genoptix, Inc.